The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules
With the COVID-19 pandemic behind us, the U.S. Food and Drug Administration (FDA) has approved 55 new drugs in 2023, a figure consistent with the number authorized in the last five years (53 per year on average). Thus, 2023 marks the second-best yearly FDA harvest after 2018 (59 approvals) in all th...
Main Authors: | Beatriz G. de la Torre, Fernando Albericio |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-01-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/29/3/585 |
Similar Items
-
The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2023-01-01) -
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2019-02-01) -
The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2020-02-01) -
The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2018-02-01) -
The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
by: Beatriz G. de la Torre, et al.
Published: (2017-02-01)